Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Small Cell Lung Carcinoma: early-phase trial registry
12 of 19 indexed Small Cell Lung Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #902 of 28,707 conditions by registered trial count.
19 US clinical trials · 12 currently recruiting · #902 of 28,707 conditions by registered trial count
Small Cell Lung Carcinoma: 19 US clinical trials tracked, 12 recruiting.
Small Cell Lung Carcinoma is the subject of 19 registered US clinical trials on ClinicalTrials.gov, 12 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 3 of these trials.
Enrollment posture brief
Registry condition small-cell-lung-carcinoma
OPEN 12 | RECR 63% | LATE 2 | EARLY 15 | RANK #902 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Cervical Spinal Cord Injury (63% recruiting · 19 trials)
Small Cell Lung Carcinoma lists 12 open slots (63% of 19 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Small Cell Lung Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Small Cell Lung Carcinoma is recruiting above its size-band peers.
12 of 19 indexed trials (63.2%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Small Cell Lung Carcinoma research.
Memorial Sloan Kettering Cancer Center accounts for 3 of 19 trials (15.8%). 15 distinct sponsors appear on at least one study for this condition label.
-
Typical Small Cell Lung Carcinoma enrolment sits around 110 participants.
Median target enrolment is 110 among the 19 trials that report a genuine target (sentinel values excluded). 9 of those (47.4%) plan for fewer than 100 participants.
-
Small Cell Lung Carcinoma research is mostly interventional.
18 interventional and 1 observational studies make up this index (94.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
19 total, page 1 of 1
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT06131840
Biology of Young Lung Cancer Study: The YOUNG LUNG Study
Dana-Farber Cancer Institute
NCT05265429
A Study of LY4175408 in Participants With Advanced Cancer
Eli Lilly and Company
NCT07046923
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
Boehringer Ingelheim
NCT05882058
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Novartis Pharmaceuticals
NCT07006727
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
Merck Sharp & Dohme
NCT04938817
A Study of Hospital-at-Home for People Receiving Tarlatamab
Memorial Sloan Kettering Cancer Center
NCT06957314
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
Memorial Sloan Kettering Cancer Center
NCT05419076
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
Memorial Sloan Kettering Cancer Center
NCT04199741
Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)
Washington University School of Medicine
NCT07155200
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
University of Maryland, Baltimore
NCT05450965
Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer
UNC Lineberger Comprehensive Cancer Center
NCT05620342
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
Merck Sharp & Dohme
NCT05224141
Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)
Amgen
NCT03319940
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Cybrexa Therapeutics
NCT04902872
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers
Washington University School of Medicine
NCT05616624
Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone
Bristol-Myers Squibb
NCT01450761
A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
AbbVie (prior sponsor, Abbott)
NCT00445198
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers
National Cancer Institute (NCI)
NCT00926640
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 12 |
| Phase 2 | 3 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Small Cell Lung Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Small Cell Lung Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Small Cell Lung Carcinoma page
19 registered trials, 12 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 12 Small Cell Lung Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Small Cell Lung Carcinoma trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Small Cell Lung Carcinoma condition card totals 19 registered trials; most-linked intervention Etoposide; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.